Merrin C, Takita H, Beckley S, Kassis J
J Urol. 1977 Mar;117(3):291-5. doi: 10.1016/s0022-5347(17)58438-4.
There were 37 patients with stages II and III testicular tumors treated by a combination of multisequential chemotherapy and radical reductive surgery. Two protocols were used: 30 patients received bleomycin, vinblastine, platinum, doxorubicin hydrochloride, cyclophosphamide and actinomycin D (protocol A), and 7 patients received bleomycin, vinblastine, vincristine, platinum and actinomycin D (protocol B). A complete clinical remission was achieved in 19 of the 37 patients (51.3 per cent), for an average survival of 12.9 months to date. A partial clinical remission was obtained in 7 patients (18.9 per cent), for an average survival of 14.2 months. Eleven of the patients (29.7 per cent) escaped from therapeutic control. The collective response (complete and partial clinical remissions) represented 70.2 per cent of the patients (26 of 37), with an average survival of 14.8 months. A new approach for the simultaneous excision of metastases in the abdomen and the chest is described and the rational basis for the combination treatment of these tumors is discussed.
37例II期和III期睾丸肿瘤患者接受了多序贯化疗和根治性减瘤手术联合治疗。采用了两种方案：30例患者接受博来霉素、长春碱、铂、盐酸阿霉素、环磷酰胺和放线菌素D（方案A），7例患者接受博来霉素、长春碱、长春新碱、铂和放线菌素D（方案B）。37例患者中有19例（51.3%）实现了完全临床缓解，迄今为止平均生存期为12.9个月。7例患者（18.9%）获得了部分临床缓解，平均生存期为14.2个月。11例患者（29.7%）脱离了治疗控制。总体缓解率（完全和部分临床缓解）为70.2%（37例中的26例），平均生存期为14.8个月。本文描述了一种同时切除腹部和胸部转移灶的新方法，并讨论了这些肿瘤联合治疗的合理依据。
